ERBB2 and breast cancer: Despite mostly positive results, the trials in the HER2 + BC, as in the HR+/HER2− space, only show a pCR and response rates benefits rather than efficacy-driven endpoints, which adds to the growing body of evidence linking ICI with pCR.